ENGN
NASDAQ HealthcareenGene Holdings Inc. - Common Stock
Biotechnology
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
๐ Market Data
| Price | $7.25 |
|---|---|
| Volume | 226,354 |
| Market Cap | 485.67M |
| Beta | -0.050 |
| RSI (14-Day) | 47.1 |
| 200-Day MA | $7.37 |
| 50-Day MA | $7.84 |
| 52-Week High | $12.25 |
| 52-Week Low | $2.65 |
| Forward P/E | -3.82 |
| Price / Book | 1.72 |
๐ฏ Investment Strategy Scores
ENGN scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (67/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (13/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ENGN in your text
Paste any article, transcript, or post โ the tool will extract ENGN and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.